Gastric retentive dosage forms: A review

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 20, Issue 6, 2003, Pages 461-497

  Hou, Sui Yuen Eddie ^a   Cowles, Verne E ^a   Berner, Bret ^a  

^a Pharmacokinetics Depomed Inc   (United States)

Author keywords

Bioadhesion; Food effect; Gastric retention; Oral drug delivery

Indexed keywords

CONTROLLED DRUG RELEASE; DRUG DOSAGE FORM; FLOTATION; GASTROINTESTINAL MOTILITY; REVIEW; STOMACH ABSORPTION; STOMACH EMPTYING; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; GASTROINTESTINAL TRANSIT; HUMAN; INTESTINE ABSORPTION; METABOLISM; MUCUS; PHYSIOLOGY; STOMACH; TABLET;

ANIMALS; DELAYED-ACTION PREPARATIONS; GASTRIC EMPTYING; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINAL ABSORPTION; MUCUS; STOMACH; TABLETS;

EID: 3142526423     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i6.30     Document Type: Review

References (136)

1. Moes A. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 1993; 10: 143-195.
2. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 1998; 15:243-284.
3. Sheth PR, Tossounian JL. Sustained release pharmaceutical capsules. US Patent 4,126,672, 1978.
4. Sheth PR, Tossounian JL. Sustained release tablet formulations. US Patent 4,140,755, 1979.
5. Michaels AS, Bashaw JD, Zaffaroni A. Gastro-inflatable drug delivery device. US Patent 3,901,232, 1975.
6. Banker GS. Sustained release film-coated preparations. US Patent 3,896,792, 1975.
7. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm 1996; 136:115-122.
8. Kim JS, Oberle RL, Krummel DA, Dressman JB, Fleisher D. Absorption of ACE inhibitors from small intestine and colon. J Pharm Sci 1994; 83:1350-1356.
9. Dressman JB, Amidon GL, Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci 1985; 74:588-589.
10. Bond JS, Beynon RJ. Proteolysis and physiological regulation. Molec Aspects Med 1987; 9:173-287.
11. Baumgartner S, Tivadar A, Vrecer V, Kristl J. Development of floating tablets as a new approach to the treatment of Heliobacter pylori infections. Acta Pharm 2001; 51: 21-33.
12. Hejazi R, Amiji M. Stomach-specific anti-H. pylori therapy. II. Gastric residence studies of tetracycline-loaded chitosan microspheres in gerbils. Pharm Dev Technol 2003; 8:252-262.
13. Mojaverian P, Ferguson RK, Vlasses PH, Rocci ML Jr, Oren A, Fix JA, Caldwell LJ, Gardner C. Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition. Gastroenterology 1985; 89:392-397.
14. Mojaverian P, Rocci ML, Conner DP, Abrams WB, Vlasses PH. Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. Clin Pharmacol Ther 1987; 41:11-17.
15. Davis SS, Hardy JG, Taylor MJ, Stockwell A, Whalley DR, Wilson CG. The in vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy. J Pharm Pharmacol, 1984; 36:740-742.
16. Davis SS, Stockwell AF, Taylor MJ, Hardy JG, Whalley DR, Wilson CG, Bechgaard H, Christensen FN. The effect of density on the gastric emptying of single- and multiple-unit dosage forms. Pharm Res 1986; 3:208-213.
17. 111In-labeled hydroxypropylcellulose matrices. Pharm Res 1989; 6:274-278.
18. Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 1991; 8:360-364.
19. Coupe AJ, Davis SS, Evans DF, Wilding IR. Correlation of the gastric emptying of non-disintegrating tablets with gastrointestinal motility. Pharm Res 1991; 8:1281-1285.
20. Itoh T, Higuchi T, Gardner CR, Caldwell L. Effect of particle size and food on the gastric residence time of non-disintegrating solids in beagle dogs. J Pharm Pharmacol 1986; 38:801-806.
21. Davis SS, Khosla R, Wilson CG, Washington N. Gastrointestinal transit of a controlled release pellet formulation of tiaprofenic acid and the effect of food. Int J Pharm 1987; 35:253.
22. Khosla R, Davis SS. Effect of tablet size on the gastric emptying of non-disintegrating tablets. Int J Pharm 1990; 62:R9.
23. O'Reilly S, Wilson CG, Hardy JG. The influence of food on the gastric emptying of multiparticulate dosage forms. Int J Pharm 1987; 34:213.
24. Blok D, Arndt JW, DeHaan FH, Vermij P, Junginger HE, Pauwels EK. Scinitgraphic investigation of the gastric emptying of 3 mm pellets in human volunteers. Int J Pharm 1995; 123:145.
25. Johnson LR. Gastrointestinal Physiology. 5 ed. St. Louis, MO: Mosby, 1997, 33-51.
26. Davenport HW. A Digest on Digestion. Chicago, IL: Yearbook Medical Publishers, 1975; 19-34, 57-62, 67-72.
27. Timmermans J, Moes AJ. Cutoff size for gastric emptying of dosage forms. J Pharm Sci 1993; 82:854.
28. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000; 63:235-259.
29. Fell JT, Whitehead L, Collett JH. Prolonged gastric retention: using floating dosage forms. Pharm Tech 2000; 24:82-89.
30. Curatolo WJ, Lo J. Gastric retention system for controlled drug release. US Patent 5,002,772, 1991.
31. Curatolo WJ, Lo J. Gastric retention system for controlled drug release. US Patent 5,443,843, 1995
32. Caldwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4,767,627, 1988.
33. Cargill RC, Caldwell LJ, Engle K, Fix JA, Porter PA, Gardner CR. Controlled gastric emptying. 1. Effects of physical properties on the residence times of nondisintegrating geometric shapes in beagle dogs. Pharm Res 1989; 5:533-536.
34. Cargill RC, Engle K, Gardner CR, Porter PA, Sparer RV, Fix JA. Controlled gastric emptying. 2. In vitro erosion and gastric residence time erodible device in beagle dogs. Pharm Res 1989; 6:506-509.
35. Caldwell LJ, Gardner, CR Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4,735,804, 1988.
36. Caldwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4,767,627, 1988.
37. Caldwell LJ, Gardner CR, Cargill RC, Higuchi T. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4,758,436, 1988.
38. Fleshner-Barak M, Lerne IE, Rosenberger V, Dahan M, Imakov Y. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition. WIPO PCT WO 02/00213 A1, 2002.
39. Asmussen B, Cremer K, Hoffman HR, Ludwig K, Roreger M. Expandable gastroretentive therapeutic system with controlled active substance release in the gastrointestinal tract. US Patent 6,290,989, 2001.
40. Jimenez-Castellanos MR, Hussein Z, Rhodes CT. Mucoadhesive delivery systems. Drug Dev Ind Pharm 1993; 19:143-194.
41. Park H. On the mechanism of bioadhesion. PhD Dissertation, The University of Wisconsin-Madison. 1986.
42. Park H, Robinson JR. Mechanisms of mucoadhesion of poly(acrylic acid) hydrogels. Pharm Res 1987; 4:457-464.
43. 14C-labeled poly(acrylic acid) dispersions. Int J Pharm 2002; 236:87-96.
44. Cuña M, Alonso MJ, Torres D. Preparation and in vivo evaluation of mucoadhesive microparticles containing amoxycillin-resin complexes for drug delivery to the gastric mucosa. Eur J Pharm Biopharm 2001; 51:199-205.
45. Phillipson M, Atuma C, Henriksen J, Holm L. The importance of mucus layers and bicarbonate transport in preservation of gastric juxtamucosal pH. Am J Physiol Gastrointest Liver Physiol 2002; 282:G211-G219.
46. Sarna SK, Otterson MR, Cowles, VE, Telfor GL. Myogenic, neural and chemical control of small intestinal motor activity. In: Jensen SL, Gregerson H, Amiri MS, Moody F, editors. Essentials of Experimental Surgery: Gastroenterology. Reading, UK: Harwood Academic Publishers, 1996.
47. Mason GR, Kahrilas PJ, Otterson MF, Lang IM, Telford GL, Telford SW, Srana SK, Cowles VE, Koch TR, et al. The digestive system. In: O'Leary JP, editor. The Physiologic Basis of Surgery. 2 ed. Baltimore, MD: Williams and Wilkens, 1996.
48. Meyer JH. Motility of the stomach and gastroduodenal junction. In: Johnson LR, editor. Physiology of the Gastrointestinal Tract. 1 vol. 2 ed. New York: Raven, 1987.
49. Sanders KM, Vogalis F. Organization of electrical activity in the canine pyloric canal. J Physiol 1989; 416:49-66.
50. Mockiki E, Kuwano H, Nakabayashi T, Garcia M, Haga N, Asao T. Pyloric relaxation regulated via intramural neural pathway of the antrum. Dig Dis Sci 2001; 46: 2307-2313.
51. Cowles VE, Nellans HN, Seifert TR, Besecke LM, Segreti JA, Mohning KM, Faghih R, Verlinden MH, Wegner CD. Effect of novel motilide ABT-229 versus erythromycin and cisapride on gastric emptying in dogs. J Pharmacol Exp Ther 2000; 293:1106-1111.
52. Houghton LA, Read NW, Heddle R, Horowitz M, Collins PJ, Chatterton B, Dent J. Relationship of motor activity of the antrum, pylorus, and duodenum to gastric emptying of a solid-liquid mixed meal. Gastroenterology 1988; 94:1285-1291.
53. Hinder RA, Kelly KA. Canine gastric emptying of solids and liquids. Am J Physiol 1977; 233:E335-E340.
54. Morz CT, Kelly KA. The role of the extrinsic antral nerves in the regulation of gastric emptying. Surg Gynecol Obstet 1977; 145:369-377.
55. Meyer JH, Dressman J, Fink A, Amidon G. Effect of size and density on canine gastric emptying of non-digestible solids. Gastroenterology 1985; 89:805-813.
56. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27:886-892.
57. Davis SS, Norring-Chrestensen F, Khosla R, Feely LC. Gastric emptying of large single unit dosage forms. J Pharm Pharmacol 1988; 40:205-207.
58. Steingoetter A, Kunz P, Weishaupt D, Mader K, Lengsfeld H, Thurshirn M, Boesiger P, Fried M, Schwizer W. Analysis of the meal-dependent intragastric performance of a gastric-retentive tablet assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003; 18:713-720.
59. Allen A. Structure and function of gastrointestinal mucus. In: Johnson LR, editor. Physiology of the Gastrointestinal Tract. New York: Raven, 1981.
60. Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001; 280:G922-G929.
61. Gusler G, Gorsline J, Levy G, Zhang SZ, Weston IE, Naret D, Berner B. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol 2001; 41:655-661.
62. Gusler G, Hou SYE, Connor AL, Wilding IR, Berner B. Pharmacoscintigraphic evaluation of metformin ER in healthy volunteers. Pharm Sci 2003; 5:S1.
63. Shell JW, Louie-Helm J, Markey M. Extending the duration of drug release within the stomach during the fed mode. US Patent 6,635,280, 2003.
64. Shell JW, Louie-Helm J, Markey M. Extending the duration of drug release within the stomach during the fed mode. US Patent 6,340,475, 2002.
65. Shell JW, Louie-Helm J. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter. US Patent 5,972,389, 1999.
66. Chawla G, Gupta P, Koradia V, Bansal AK. Gastroretention: a means to address regional variability in intestinal drug absorption. Pharm Tech 2003; 27:50-68.
67. Sugito K, Ogata H, Goto H, Kaniwa N, Takahata H, Samejima M. Gastric emptying rate of drug preparations III. Effects of size of enteric micro-capsules with mean diameters ranging from 0.1 to 1.1 mm in man. Pharm Soc Jpn 1992; 40: 3343-3345.
68. Lobo DN, Bostock KA, Bush D, MacDoanld IA, Perkins AC, Neal KR, Rowlands BJ, Allison SP. Reproducibility and normal ranges for gastric emptying in normal volunteers using a test meal designed for post-operative patients. Nuclear Med Comm 2002; 23:97-101.
69. Beten DB, VanGesbeke B, Schoutens A, Moes AJ. Evaluation of the gastric behavior of coevaporate particles under fasting and non-fasting conditions. Int J Pharm, 1995; 123:145.
70. Timmermans J, Moes AJ. Factors controlling the buoyancy and gastric retention capabilities of floating capsules: new data for reconsidering the controversy. J Pharm Sci 1994; 83:18-24.
71. Cowles VE, Myrback MJ. Gastric retention dose response to food or olive oil in beagles. Unpublished data, 2000.
72. Chen TF, Hou SYE, Connor AL, Wilding IR, Berner B. Scintigraphic evaluation of gastric retentive tablets in healthy volunteers. Unpublished data, 2003.
73. Wilding IR, Davis SS, Sparrow RA, Ziemniak JA, Heald DL. Pharmacoscintigraphic evaluation of a modified release (Geomatrix) diltiazem dosage. J Control Release 1995; 33:89-97.
74. Shameem M, Katori N, Aoyagi N, Kojima S. Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasted and fed conditions. Pharm Res 1995; 12:1049-1054.
75. Louie-Helm J, Fell R, Gusler G, Hou SYE, Cowles V, Urquhart J, Berner B, Wilding IR. Dual-labeled pharmacoscintigraphic study of furosemide gastric retentive (GR™) tablets in healthy volunteers. CRS 30th Annual Meetings Proceedings 2003; 118.
76. Louie-Helm J, Berner B, Urquhart J. Formulation of an erodible, gastric retentive oral diuretic. US Patent Application 20030152622, August 14, 2003.
77. Berner B, Louie-Helm J. Gastric retentive oral dosage forms with restricted drug release in the lower gastrointestinal tract. US Patent Application 2003014052, June 5, 2003.
78. Louie-Helm J, Berner B. Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data. US Patent Application 20030091630, May 15, 2003.
79. Timmins P, Dennis AB, Vyas KA. Biphasic controlled release delivery system for high solubility pharmaceuticals and method. US Patent 6,475,521, 2002.
80. Timmins P, Dennis AB, Vyas KA. Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method. US Patent 6,660,300, 2003.
81. Physicians' Desk Reference, 57 ed. Montvale, NJ: Thompson PDR, 2003.
82. Depomed completes dosing in Phase III trials of metformin GR™ and ciprofloxacin GR™. Business Wire Press, November, 2003.
83. Louie-Helm J, Berner B, Fell R, Shell JN, Dye D, Levy G, Gorsline J, Mueller M, Dilger C. Pharmacokinetics of ciprofloxacin gastric retentive tablets in healthy volunteers. CRS 28th Annual Meetings Proceedings 2001; 6044.
84. Depomed initiates Phase II trial with once daily diuretic furosemide GR. Business Wire Press Release, January, 2004.
85. Fix JA, Cargill R, Engle K. Controlled gastric emptying. III. Gastric residence time of a nondisintegrating geometric shape in human volunteers. Pharm Res 1993; 10: 1087-1089.
86. Sonobe T, Masataka K, Takamatsu N, Konno Y, Takagi H. Gastric retention device. European Patent Appl. 0415671B1, 1995.
87. Shalaby WSW, Blevins WE, Park K. Use of ultrasound imaging and fluoroscopic imaging to study gastric retention of enzyme-digestible hydrogels. Biomaterials 1992; 13:289-296.
88. Shalaby WSW, Park K, Blevins WE. New analytical methods to study the gastric retention of albumin-crosslinked hydrogels in dogs. Proc Int Symp Control Release Bioact Mater 1990; 17:132-133.
89. Park K, Oark H. Super absorbent hydrogel foams. US Patent 5,750,585, 1998.
90. Chen J, Blevins WE, Park H, Park K. Gastric retention properties of superporous hydrogel composites. J Control Release 2000; 64:39-51.
91. Gemeinhart RA, Park HA, Park K. Effect of compression on fast swelling of poly(acrylamide-co-acrylic acid) superporous hydrogels. J Biomed Mater Res 2001, 55:54-62.
92. Gutierrez-Rocca J, Dunne J, Lally M. Release pharmaceutical construct for gastric retention. US Patent Appl. 2003/0008007 A1.
93. Sinnreich J. Covered retard forms. US Patent 4,996,058, 1991.
94. Wilson AM, McKenna B, Gudipati M, Desmond A, Prosser E, Cumming KI, Cowles VE, Myrback RM, Hou SY, Berner B. Evaluation of endogastric therapeutic system (EGTS) containing a GABA receptor agonist in dogs. AAPS Pharm Sci 2001; 3.
95. Cumming KI, Wilson AM, McKenna B, Conaghey O, Desmond A, Ramtoola Z, Wilding IR, Wallis SJ, Hou SYE, Cowles V, Berner B, Martin M. The pharmacokinetic and pharmacoscintigraphic evaluation of endogastric therapeutic systems in the fasted and fed state in healthy volunteers. AAPS Pharm Sci 2001; 3.
96. Lavy E, Klausner E, Hoffman A, Friedman M. Evaluation of a novel sustained-release gastroretentive dosage form of riboflavin in dogs. J Vet Intern Med 2001; 15:304.
97. Klausner EA, Lavy E, Stepensky D, Cserepes E, Barta M, Friedman M, Hoffman A. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. J Clin Pharamcol 2003; 43:711-720.
98. Klausner EA, Eyal S, Friedman M, Hoffman A. Novel levodopa gastroretentive dosage form: in vivo evaluation in dogs. J Control Release 2003; 88:117-126.
99. Klausner EA, Lavy E, Stepensky D, Friedman, M, Hoffman A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm Res 2002; 19:1516-1523.
100. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release 2003; 90:143-162.
101. Jusko WJ, Rennick BR, Levy G. Renal excretion of riboflavin in the dog. Am J Physiol 1970; 4:1046-1053.
102. Jusko WJ, Levy G. Pharmacokinetic evidence for saturable renal tubular reabsorption of riboflavin. J Pharm Sci 1970; 59:765-772.
103. Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of the overall response. Kidney Int 1982; 22:69-74.
104. Waller ES, Hamilton SF, Massarella JW, Sharanevych MA, Smith RV, Yakatan GJ, Dolusio JT. Disposition and absolute bioavailability of furosemide in healthy males. J Pharm Sci 1982; 71:1105-1108.
105. Desai S, Bolton S. A floating controlled-release devlivery system: in vitro-in vivo evaluation. Pharm Res 1993; 10:1321-1325.
106. Oth M, Franz M, Timmermans J, Moës A. The bilayer floating capsule: a stomach-directed drug delivery system for misoprostol. Pharm Res 1992; 9:298-302.
107. Agyilirah GA, Green M, DuCret R, Banker GS. Evaluation of the gastric retention properties of a cross-linked polymer coated tablet versus those of a non-disintegrating tablet. Int J Pharm 1991; 75:241-247.
108. Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxycillin trihydrate. Int J Pharm 1992; 86:79-88.
109. Devereux JE, Newton JM, Short MB. The influence of density on the gastrointestinal transit of pellets. J Pharm Pharmacol 1990; 42:500-501.
110. Clarke GM, Newton JM, Short MB. Comparative gastrointestinal transit of pellet systems of varying density. Int J Pharm 1995; 114:1-11.
111. Reddy LH, Murthy RS. Floating dosage systems in drug delivery. Crit Rev Ther Drug Carrier Sys 2002; 19:553-585.
112. Müller-Lissner SA, Blum AL. The effect of specific gravity and eating on gastric emptying of slow-release capsules. N Engl J Med 1981; 304:1365.
113. Sheth PR, Tossounian J. The hydrodynamically balanced system (HBSTM): a novel drug delivery system for oral use. Drug Dev Ind Pharm 1984; 10:319-339.
114. Gabr KE, Borg ThM. Formulation and evaluation of buffered floating furosemide delivery systems. STP Pharma Sci 2000; 10:181-186.
115. Nur AO, Zhang JS. Captopril floating and/or bioadhesive tablets: design and release kinetics. Drug Dev Ind Pharm 2000; 26:965-969.
116. Özdemir N, Sefika O, Özkan Y. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations. Drug Dev Ind Pharm 2000; 26:857-866.
117. Wei Z, Yu Z, Bi D. Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug. Drug Dev Ind Pharm 2001; 27:469-474.
118. Yang L, Eahraghi J, Fassihi R. A new intragstric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. J Control Release 1999; 57:215-222.
119. Whitehead L, Fell JT, Collett JH, Sharma HL, Smith AM. Floating dosage forms: in vivo study demonstrating prolonged gastric retention. J Control Release 1998; 55: 3-12.
120. Whitehead L, Collett JH, Fell JT. Amoxycillin release from a floating dosage form based on alginates. Int J Pharm 2000; 210:45-49.
121. Murata Y., Kofuji K, Kawashima S. Preparation of floating alginate gel beads for drug delivery to the gastric mucosa. J Biomater Sci Polymer Ed 2003; 14:581-588.
122. Iannuccelli V, Coppi G, Fontanna LE, Bernabei MT. PVP solid dispersions for the controlled release of furosemide from a floating multiple-unit system. Drug Dev Ind Pharm 2000; 26:595-603.
123. Rouge N, Alléman E, Gex-Fabry M, Balant L, Cole ET, Buri P, Doelker E. Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. Pharm Act Helv 1998; 73:81-87.
124. Warrington SJ, Barclay SP, John VA, Shotton PA, Wardle HM, Good WR. Influence of site of drug delivery on the systemic availability of metoprolol: comparison of intragastric infusion and 14/190 Oros administration. Br J Clin Pharmacol 1985; 19: 219S-224S.
125. Atyabi F, Sharma HL, Mohammad HAH, Fell JT. In vivo evaluation of a novel gastric retentive formulation based on ion-exchange resins. J Control Release 1996; 42: 105-113.
126. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm 2002; 241:279-292.
127. Soppimath KS, Kulkarni AR, Rudzinski WE, Aminabhavi TM. Microspheres as floating drug delivery systems to increase gastric retention of drugs. Drug Metab Rev 2001; 33:149-160.
128. Deacon MP, McGurk S, Roberts CJ, Williams PM, Tendler SJB, Davies MC, Davis, SS, Harding SE. Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem J 2000; 348:557-563.
129. Säkkinen M, Jurjenson H, Marvola M, Tuononen T, Veski P. Evaluation of microcrystalline chitosans for gastro-retentive drug delivery. Eur J Pharm Sci 2003; 19: 345-353.
130. Hejazi R, Amiji M. Stomach-specific anti-H.pylori therapy. II. Gastric residence studies of tetracycline-loaded chitosan microspheres in gerbils. Pharm Dev Tech 2003; 8: 253-262.
131. Wang J, Tabata Y, Bi D, Morimoto K, Tabata Y, Ikada Y. Evaluation of gastric mucoadhesive properties of aminated gelatin microspheres. J Control Release 2001; 73:223-231.
132. AHFS Drug Information, Bethesda, MD. American Society of Health System Pharmacist, 2003, 2834-2836.
133. Li SP, Pendharkar CM, Mehta GN, Karth MG, Feld KM. Sucralfate as a bioadhesive gastric intestinal retention system: preliminary evaluation. Drug Dev Ind Pharm 1993; 19:2519-2537.
134. Higo S, Kawashima Y, Takeuchi H, Hino T, Yamamoto H. Gastric mucoadhesive properties of the solid dispersed complex of sucralfate and terracycline for Helicobacter pylori eradication. Pharm Res 1997; 14:S537-S538.
135. Umamahesware RB, Jain S, Tripathi PK, Agrawal G.P, Jain, NK. Floating-bioadhesive microspheres containing acetohyroxamic acid for of Helicobacter pylori. Drug Deliv 2003; 9:223-231.
136. El-Gibaly I. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. Int J Pharm 2002; 249:7-21.